Welcome to the NEO-Empower clinical study!
Learn about the NEO-Empower clinical study
Diagnosed with early-stage non-small cell lung cancer (NSCLC)? You’re not alone.
This website provides information about a clinical study, NEO-Empower, for adults with NSCLC that has been diagnosed at an early stage and can be removed by surgery. Recently, the combination of chemotherapy with immunotherapy (specifically, a type of immunotherapy called a “PD-1 inhibitor”) has been shown to be effective for early-stage NSCLC by reducing the risk of tumor recurrence after surgery as compared to chemotherapy alone. However, many patients still have recurrence of their cancer. This study has been designed to find out whether adding an additional anti-cancer drug to the combination of chemotherapy and a PD-1 inhibitor before surgery might further reduce the risk of cancer recurrence after surgery.
Clinical studies are essential for investigating potential treatments and are not possible without the people who take part. Everyone involved in this clinical study plays an important role in increasing our understanding of early-stage NSCLC, which may help others in the future with this condition.
A lung cancer diagnosis may feel overwhelming, and you may feel that you have enough to do without committing to a clinical study. However, you may play a key role in helping to develop therapies that advance our medical knowledge of early-stage NSCLC. Every treatment that exists today is available because of study participants who actively took part in research.
English 
French 
Spanish 
Catalan (Spain) 
German